Drugs that contain Cobimetinib Fumarate
1. Cotellic patents expiration
COTELLIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(5 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(12 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(12 years from now) | |
| US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(2 years from now) | |
| US11597699 | GENENTECH INC | MEK inhibitors and methods of their use |
Oct, 2026
(2 years from now) | |
|
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(2 years from now) | |
|
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(6 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(10 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(10 years from now) | |
|
US10478400 (Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(12 years from now) | |
|
US11254649 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(12 years from now) | |
|
US10590102 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-902) | Oct 28, 2025 |
| M(M-278) | Jul 28, 2025 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma; As a single agent for the treatment of adult patients with histiocytic neoplasms
Dosage: TABLET;ORAL
More Information on Dosage
COTELLIC family patents
